Who
Franklin M. Berger
Director
Company insider
Files Form 4 as: Director, Retension Pharmaceuticals; Director, Atea Pharmaceuticals; Director, Kezar Life Sciences; Director, ESSA Pharma; Director, Rain Oncology; Director, Atreca; Director, Five Prime Therapeutics; Director, Proteostasis Therapeutics.
In numbers
- Trades disclosed
- 243
- Buys
- 43
- Sells
- 11
- Bought
- $15.3M
- Sold
- $2.6M
- Companies
- 14
- Companies where not an officer
- 14
- First trade
- 19 May 2006
- Last trade
- 13 Oct 2026
- Last filed
- 13 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 13 Oct 2026filed 13 Oct 2026 | RTSN Retension PharmaceuticalsBiotechnology | SEC FORM 4 Code C | —12,517 | filing |
| 13 Oct 2026filed 13 Oct 2026 | RTSN Retension PharmaceuticalsBiotechnology | SEC FORM 4 Bought | $120K10,000 at $12.00 | filing |
| 13 Oct 2026filed 13 Oct 2026 | RTSN Retension Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code C | —12,517 | filing |
| 8 Oct 2026filed 8 Oct 2026 | RTSN Retension Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,636 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | AVIR Atea PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —29,600 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | AVIR Atea Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —29,600 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | AVIR Atea Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —26,700 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | AVIR Atea Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —29,600 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | AVIR Atea Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —26,700 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | AVIR Atea Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —37,700 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | AVIR Atea Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —37,700 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | AVIR Atea PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —29,600 at $0.00 | filing |
| 11 May 2026filed 11 May 2026 | Kezar Life SciencesBiotechnology | SEC FORM 4 Code U | —89,069 | filing |
| 11 May 2026filed 11 May 2026 | Kezar Life Sciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —3,500 at $0.00 | filing |
| 11 May 2026filed 11 May 2026 | Kezar Life Sciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —5,000 at $0.00 | filing |
| 11 May 2026filed 11 May 2026 | Kezar Life Sciencesoption or derivative | SEC FORM 4 Code D | —3,500 at $0.00 | filing |
| 11 May 2026filed 11 May 2026 | Kezar Life Sciencesoption or derivative | SEC FORM 4 Code D | —5,000 at $0.00 | filing |
| 11 May 2026filed 11 May 2026 | Kezar Life Sciencesoption or derivative | SEC FORM 4 Code D | —5,000 at $0.00 | filing |
| 11 May 2026filed 11 May 2026 | Kezar Life Sciencesoption or derivative | SEC FORM 4 Code D | —2,600 at $0.00 | filing |
| 11 May 2026filed 11 May 2026 | Kezar Life Sciencesoption or derivative | SEC FORM 4 Code D | —2,600 at $0.00 | filing |
News
Retension Pharmaceuticals IPO priced at $12, raising $45 millionRTSN · 247wallst.com · 9 Oct 2026
0 headlines in the last 90 days name Franklin M. Berger; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.